Achalasia

The central pharmacologic target in achalasia is the abnormally high tone of the lower esophageal sphincter. Loss of inhibitory myenteric signaling, particularly signaling associated with nitric oxide, leaves excitatory influence relatively unopposed. Drugs that reduce sphincter contraction can therefore improve passage of retained food, but they do not restore the damaged neural circuitry or normal peristalsis.

Nitrates and calcium channel blockers provide temporary smooth-muscle relaxation at the sphincter rather than definitive correction of achalasia. Their clinical value lies in lowering resistance to esophageal emptying and easing dysphagia for a limited period. Because the underlying neuronal degeneration and impaired peristalsis remain, symptom improvement may be incomplete or short-lived, which limits their role in long-term management.

Endoscopic botulinum toxin acts at the neuromuscular junction by inhibiting acetylcholine release. Reduced cholinergic stimulation decreases contraction of the lower esophageal sphincter and can promote its relaxation. This approach differs from oral smooth-muscle relaxants because it delivers the pharmacologic intervention endoscopically to the affected region. Its benefit is generally temporary, so repeat or alternative treatment may be needed.

Pharmacologic or endoscopic botulinum toxin approaches may be considered when a patient cannot undergo pneumatic dilation, surgical myotomy, or peroral endoscopic myotomy. They are relevant when symptom relief is needed without proceeding directly to an intervention that can provide more durable control. Their main limitation is that relaxation and dysphagia relief may not persist as long as the effects of definitive therapies.

Pneumatic dilation, surgical myotomy, and peroral endoscopic myotomy directly address resistance at the lower esophageal sphincter rather than only producing temporary pharmacologic relaxation. Consequently, they generally offer more durable symptom control than nitrates, calcium channel blockers, or botulinum toxin, which are valuable mainly when definitive therapy is unsuitable or unavailable.

The main outcomes are changes in swallowing difficulty and the ability to move food through the esophagus, since retained food reflects impaired emptying. Relief should be interpreted as symptomatic and potentially short term, not as evidence that peristalsis or inhibitory neural signaling has recovered. This distinction helps determine whether temporary treatment remains useful or whether a definitive option should be considered.